Effect of age on toxicokinetics among human volunteers exposed to propylene glycol methyl ether (PGME) by Hopf, Nancy B. et al.
Hopf, N.B.; Vernez, D.; Berthet, A..; Charrière, N.; Arnoux, C.; Tomicic, C. Effect of 
age on toxicokinetics among human volunteers exposed to propylene glycol 
methyl ether (PGME).   Toxicology Letters, 211(1) :77-84, 2012. 
 
Postprint version Final draft post-refereeing 
Journal website http://www.sciencedirect.com/science/journal/03784274  
Pubmed link http://www.ncbi.nlm.nih.gov/pubmed/22421272  
DOI 10.1016/j.toxlet.2012.02.018 
 
 
1 
 
Effect of age on toxicokinetics among human volunteers exposed to 
propylene glycol methyl ether (PGME)  
 
 
 
Nancy B. Hopf
1,
*, David Vernez
1
, Aurelie Berthet
1
, Nicole Charriere
1
, Christine 
Arnoux
1
, Catherine Tomicic
2
 
 
1 Institute for Work and Health  (IST), University of Lausanne, 1011 Lausanne, Switzerland 
2 Federal Office of Public Health (FOPH), Division of Chemical Products, 3003 Bern, 
Switzerland 
E-Mails: Nancy.Hopf@hospvd.ch; David.Vernez@hospvd.ch; Aurelie.Berthet@hospvd.ch; 
Nicole.Charriere@hospvd.ch; Christine.Arnoud@hospvd.ch; 
Catherine.Tomicic@bag.admin.ch    
* Author to whom correspondence should be addressed; Dr. Nancy B. Hopf, Institute for 
Work and Health  (IST), Rue du Bugnon 21, 1011 Lausanne, Switzerland Phone  +41 (0) 21 
314 9558 Fax  +41 (0)21 314 74 30 
 
 
Intended journal: Toxicology Letters 
 
  
2 
 
Abstract (max 200 words) 
 
Aging adults represent the fastest growing population segment in many countries. 
Physiological and metabolic changes in the aging process may alter how aging adults 
biologically respond to pollutants. In a controlled human toxicokinetic study (exposure 
chamber; 12m3), aging volunteers (n=10; >58 years) were exposed to propylene glycol 
monomethyl ether (PGME, CAS no. 107-98-2) at 50 ppm for 6 hours. The dose-dependent 
renal excretion of oxidative metabolites, conjugated and free PGME could potentially be 
altered by age. Aims: (1) Compare PGME toxicokinetic profiles between aging and young 
volunteers (20-25 years) and gender; (2) Test the predictive power of a compartmental 
toxicokinetic (TK) model developed for aging persons against urinary PGME concentrations 
found in this study. Methods: Urine samples were collected before, during, and after the 
exposure. Urinary PGME was quantified by capillary GC/FID. Results: Differences in 
urinary PGME profiles were not noted between genders but between age groups. Metabolic 
parameters had to be changed to fit the age adjusted TK model to the experimental results, 
implying a slower enzymatic pathway in the aging volunteers. For an appropriate exposure 
assessment, urinary total PGME should be quantified. Conclusion: Age is a factor that should 
be considered when biological limit values are developed. 
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monomethyl ether; PGME;  
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Introduction 
Aging adults represent the fastest growing population segment in many countries.  
Consequently the average age of the working population will increase.  In Switzerland, the 
percent of people older than 65 years will increase from today’s 17% to 28% in 2060 (SFSO, 
2010), which is the same trend seen in other industrialized countries (Toossi, 2009). 
Current knowledge regarding physiological changes in the aging process is known from 
pharmaceutical research, where the risk for adverse drug reactions can be devastating, 
especially in elderly patients with comorbidity and polypharmacy. Corsonello et al. (2010) 
summarized the changes due to aging as follows: decrease in hepatic drug clearance, mainly 
due to reduced blood flow and hepatocyte mass, decrease in renal function due to sclerotic 
changes in the glomeruli, and changes in pharmacodynamics in the cardiovascular and 
nervous system. The most important pharmacokinetic change in old age includes a decrease 
in the excretory capacity of the kidney, more than the decline in the rate of hepatic drug 
metabolism (ElDesoky, 2007). 
Regarding occupational health, younger (defined as those aged <25 years) and older workers 
(defined as those aged >55 years) could potentially respond to workplace exposures 
differently. Translating from pharmaceutical research among older individuals, we could 
expect aging workers to respond to workplace exposures similarly; resulting in a depressed 
clearance of the workplace pollutant.  Implications may be that current exposure risk 
management programs do not sufficiently protect the aging workers from potential health 
hazards associated with workplace exposures. 
Biological monitoring of chemical exposures is the measurement of the substances 
themselves, their metabolites and/or the induced biological effects in biological media (ex. 
urine and blood) to evaluate exposure compared to an appropriate reference value (BEI, BAT, 
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BLV). Biological monitoring programs are used to manage health risks in the workplace. 
However, these biological reference values are based on published exposure studies, and 
included both occupational and volunteer studies (ACGIH 2011); often with little or no 
information about the health of the workers and the age range selected. Large biological 
variabilities exist among individuals (Truchon et al., 2006), mainly due to absorption, 
distribution, metabolism, and elimination (ADME) processes (Sobus et al., 2010), thus 
collection times specified for the reference values might not be optimal for aging workers 
with a slower ADME. Consequently, this may lead to an under or overestimate of exposure 
depending on the substance measured. 
To help interpretation of biomonitoring results, a toxicokinetic (TK) modeling approach may 
be used since it describes the fate of chemicals in the body. The impact of age on biological 
monitoring has been explored (Tomicic and Droz, 2009) by changing the physiological 
parameters due to age in an already developed TK model (Pierrehumbert et al., 2002). Overall 
changes due to age were 10–20%, but differences up to 50% were observed (Tomicic and 
Droz, 2009). These differences appeared to depend on the chemical and the exposure 
biomarker considered. The influence of age on industrial chemical toxicokinetics has not yet 
been determined and could be a source for inter-worker variability (Truchon et al., 2006). 
In a previous human volunteer study, young (<25 years) men (n=10) and women (n=15) were 
exposed to three solvents (propylene glycol monomethyl ether (PGME, CAS no. 107-98-2), 
methyl ethyl ketone, methyl chloroform) separately, during six hours and at half their 
threshold limit values (Tomicic et al., 2011). Using an univariate analysis of variance 
adjusting for potential confounders (body mass index, body fat, genotype), the authors 
showed significant differences in the concentrations of the respective urinary exposure 
biomarkers among women, with an increase of more than 50% in metabolites concentrations 
(urinary trichloroethanol) and a decrease of up to 50% in unchanged substances 
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concentrations (urinary methyl ethyl ketone, urinary free PGME) for women under hormonal 
contraceptive regimen. The explanation provided by the authors (Tomicic et al., 2011) is an 
increase in the metabolic rate, as explained by the estrogen-regulated CYP2E1 (Kennedy, 
2008). Actually, free estradiol level is lower in women under hormonal contraceptive than in 
women without hormonal contraceptive (Bjørnerem et al., 2004). Thus, the use of hormonal 
contraceptives like the combined contraceptive pill may increase CYP2E1 activity. 
 
Consequently, the observed variabilities in toxicokinetics were not only due to physiological 
differences between genders but also an individual’s hormone levels.  These factors may lead 
to misinterpretation of biomonitoring results (Tomicic et al., 2011). Moreover, unmetabolized 
urinary fraction of PGME was found a suitable biomarker among the young volunteers 
(Tomicic et al., 2011), and can therefore be compared to the biological limit values collected 
at the end of the work shift. The biological limit value for urinary PGME is 20 mg/L in 
Switzerland (SUVA, 2011) and 15 mg/L in Germany (DFG, 2011).  
 
In the exposure chamber study of young volunteers, PGME was chosen as the substance of 
interest because it is commonly used in industry and consumer products (Dentan et al., 2000) 
and the toxicokinetics are well understood. PGME is increasingly replacing other glycol 
ethers as it is assumed to be less toxic (Dentan et al., 2000) than ethylene glycol derived 
glycol ethers, which have been associated with depression of the central nervous system. 
Commercial PGME contains 95-98 % of α-isomer (secondary alcohol) and <5% of the β-
isomer (primary alcohol). The α-isomer is eliminated through expired air or metabolized 
through the microsomal mixed function oxydase P450 and the metabolites (largely propylene 
glycol) are excreted with unchanged and conjugated PGME in urine (Miller, 1987). The β-
isomer is eliminated through expired air or metabolized through alcohol dehydrogenase 
6 
 
(ADH) followed by aldehyde dehydrogenase (ALDH) to lactate and to pyruvate, then 
excreted with conjugated PGME in urine (Miller et al., 1986). Elimination kinetics is dose-
dependent (0 order) (Kolloffel et al., 1996). At higher doses (5.1 g/day), the metabolic 
clearance is saturated, and half-lives increase (Speth et al., 1987). 
Based on current knowledge, we hypothesized that (1) there would be a difference in PGME 
toxicokinetic profiles between young (20-25 years) and aging volunteers (58- 62 years) and 
(2) the toxicokinetic model developed for aging persons (Tomicic and Droz, 2009) would 
predict well the urinary PGME concentrations in aging volunteers. The present study was 
designed to test these hypothesis; we repeated the human study of Tomicic et al. (Tomicic et 
al., 2011), but only men and women over the age of 58 years were included. Our aims of this 
study were to (1) compare the PGME toxicokinetic profiles between the young (20-25 years) 
and aging volunteers (58- 62 years) exposed to PGME (50 ppm, 6 hours), and between 
genders, and (ii) test the predictive power of the toxicokinetic model adjusted with 
physiological parameters for aging persons (Tomicic and Droz, 2009). 
 
 
METHODS 
Chemicals 
PGME (>98%) was obtained from Sigma-Aldrich (Buchs, Switzerland), tert-butoxy-2-
propanol (CAS 57018-52-7, internal standard) from Fluka (Buchs, Switzerland), and distilled 
dichloromethane, methanol, heptane (CAS 142-82-5, internal standard), anhydrous sodium 
sulfate, hydrochloric acid, and sodium hydroxide from Merck (Darmstadt, Germany). 
 
Study population 
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A total of ten volunteers (n=10) were included in the study; five men and five women. 
Exclusion criteria employed were the same as for the group of young volunteers in the 
previous study (Tomicic et al. 2011).  
It was very difficult to recruit healthy volunteers between the ages 55-65 years who did not 
smoke, use medications, and drink more than 1-3 glasses of alcohol each day. More than a 
thousand pamphlets explaining the study were distributed in waiting rooms among local 
dentists, ophthalmologists, opticians, and in fitness centers in Lausanne, Switzerland. We also 
explained our study to groups of unemployed persons over the age of 50 years who were 
attending a job training seminar, and to persons attending evening university classes. The 
most successful recruitment, however, was from displaying the pamphlet on information 
boards in a large hospital (Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, 
Switzerland). During the initial phone contact with a potential volunteer, the study was 
explained in detail and the use of medication, tobacco products, and alcohol consumption 
were used for screening. 
Selected healthy volunteers underwent a medical examination by an occupational physician 
here in our institute (the Institute of Work and Health (IST, Lausanne, Switzerland), and 
included a health questionnaire, a general physical examination (a blood sample to analyze 
common liver enzymes, spirometry, and an electrocardiogram). 
This human volunteer study was approved by the by the Clinical Research Ethics Committee 
of the Faculty of Biology and Medicine of the University of Lausanne, according to the 
Declaration of Helsinki, and all volunteers signed a written informed consent before 
participating in the study. The volunteers were reimbursed for their time and inconvenience 
CHF 200 and travel expenses. 
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Exposure conditions 
We allowed maximum two volunteers in the exposure chamber (12 m3) for each 6-hour 
exposure session, resulting in eight sessions. Each volunteer was checked by an IST physician 
just before entering and exiting the exposure chamber. The volunteers were considered at rest 
(0 Watts) during the exposure period. 
The exposure chamber have been extensively described elsewhere (Tomicic et al., 2011). 
Briefly, air renewal rate was 12-15 per hours at ambient temperature (24 ˚C) with PGME air 
concentration fixed at 50 ppm and controlled by the software Lab VIEW (National 
Instruments Corporation, Texas, USA). The PGME air concentrations were continuously 
monitored with a portable FTIR (Fourier Transform Infrared Spectroscopy) gas analyzer 
(Gasmet TM DX4015, Gasmet Technologies Oy, Helsinki, Finland) and a stationary gas 
chromatograph (GC) (Perkin Elmer) with a flame ionization detector (FID). In addition, 
personal air concentrations were collected (air sampling rate of 100 ml/min) using activated 
charcoal to confirm the actual PGME exposures. 
 
Urine collection 
Urine samples were collected before the volunteers entered the exposure chamber and every 2 
hours during exposures (in a solvent free area) for six hours. The urine was quantitatively 
collected for additional 20 hours by the volunteers themselves. The volunteers were instructed 
to continue collecting their urine in polyethylene bottles, note the collection time, and store 
the bottles in his/her refrigerator (4 ˚C) until bringing them to the laboratory the next day. The 
urine samples were immediately aliquoted after reception and stored frozen (-20 ˚C) until 
analysis. 
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Analytical methods 
Urine analysis of PGME was performed according to the method of Tomicic and Berode 
(Tomicic and Berode, 2010). In brief, quantification of urinary PGME included a gas 
chromatograph (Agilent 6890, Agilent Technologies AG, Urdorf, Switzerland) equipped with 
a capillary column (CP-Sil 8 CB, 95% dimethylpolysiloxane polymer, 5% phenyl groups; 60 
m×0.25 mm i.d., 1.00 µm film thickness Varian Chrompack Milian SA, Geneva, 
Switzerland), a multipurpose sampler (Gerstel AG, Sursee, Switzerland) operated in 
headspace mode, and a flame ionization detector. Total PGME was determined in urine 
samples (2 ml) after acidic hydrolysis (200 µl of 10 M hydrochloric acid), incubation at 100 
°C for 16 h, and neutralization with 200 µl of 10 M sodium hydroxide. We did not adjust for 
creatinine due to the passive process of elimination in the kidney (Tomicic et al., 2011). We 
used the urinary creatinine concentrations to check for the completeness of urine collection 
(Edwards et al 1969), and if creatinine concentrations were within the normal range 0.3-3.0 
g/L (WHO 1996) we deemed the urine sample complete. 
The charcoal tubes were desorbed with dichloromethane:methanol (95:5) and analyzed with 
GC/FID as described above for the urine analysis using liquid injection (Varian 3800, Varian 
Chrompack Milian SA, Geneva, Switzerland). 
 
Model description 
We used the age-adjusted TK model developed by Tomicic and Droz (2009). This model 
incorporates physiological parameters such as body weight, cardiac output, blood flows, 
volumes of the central compartment and slowly perfused tissues, renal clearances and 
metabolic constants (Pierrehumbert et al., 2002).  The age-adjusted physiological parameters 
were liver weight (- 8%), body fat (+ 30%), kidney weight (- 20%), renal blood flow (- 25%), 
hepatic blood flow (- 20%), urinary excretion rate (- 30%), and metabolic rate (- 8%). The 
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cardiac output was unchanged.  The age parameters for metabolic rates were based on values 
found among young volunteers (Tomicic and Vernez, submitted 2011). The specific 
physiological and metabolic parameters used in the model are given in table 1. This model 
was used in comparison to our experimental results. 
 
Statistical and simulation methods 
We computed the geometric mean (GM) and geometric standard deviation (GSD) for the 
demographics of the study participants.  Figures were made in Stata version 11.0 (Stata Corp 
L8, Texas, USA). The toxicokinetic model was run in Berkley Madonna software version 
8.3.18 (University of California, USA). 
 
We adjusted metabolic and physiologic parameters for curve-fitting. Occupational exposure 
scenarios at the current Swiss OEL for 8-hour/work-day and 5 days/week over four weeks 
were simulated using the obtained model. The physical workload was set at 50 W for 12 
hours per day and at 0 W the remaining of the day.  
 
Analysis of variance (ANOVA) was conducted to test whether age was a significant factor in 
the PGME toxicokinetic. Both increasing and decreasing toxicokinetic slopes were used as 
kinetics descriptors. Age, hormonal treatment, and gender were dependent variables and log 
increasing (0 -6 hrs) and log decreasing (6-16 hrs) were independent variables.  Tests were 
performed for both free and total PGME.  
 
 
RESULTS 
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A total of 11 volunteers, six women and five men, participated in our study. Table 2 
summarizes the volunteer demographics. During the study, one of the volunteers was under 
menopausal hormonal treatment, which might alter the urinary excretions of PGME as shown 
in the study among younger volunteers (Tomicic et al., 2011). We therefore decided not to 
retain this volunteer for further analysis, reducing the number of female volunteers to five 
(total n=10).  
 
The PGME air concentrations in the exposure chamber remained stable during all exposure 
sessions (49.6 ppm ± 3.70). The FTIR, GC/FID, and PGME absorbed onto the charcoal tubes 
collected using personal sampling for each session were not significantly different (p-value = 
0.3). 
 
We had a complete number of urine samples for all participants during the time in the 
exposure chamber (6 hours). After exposure ceased, the urine samples were collected ad lib. 
This resulted in missing urine sample collections for some of the 2-hour periods. 
 
Unmetabolized urinary fraction of PGME; urinary free, conjugated (free subtracted from total 
PGME), and total PGME in urine as a function of time after six hours of exposure to 187 
mg/m3 (50.9 ppm) PGME are depicted in figure 1 and 2. The concentration of PGME (free 
and total PGME) in urine rose rapidly, and did not reach an apparent plateau level during the 
six hours of exposure. The toxicokinetic profiles were similar between men and women, with 
slight differences in the maximum concentration and elimination rate. 
 
Intriguingly, the free and total PGME urinary profiles seemed to overlap, which was not noted 
for young (<25 years) individuals (Tomicic et al., 2011). The ratio between free and 
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conjugated PGME was higher in the group >58 years compared to <25 years, signifying much 
less conjugation in the older group.  The total quantities of PGME (free and conjugated) 
excreted during 6 hours were 2.8 mg for the young and 2.3 mg for the aging volunteers.   The 
age-adjusted TK model (Tomicic and Droz, 2009) did predict well for total urinary PGME 
(Figure 1) but not for urinary free PGME in the aging group (Figure 2),  
  
Consequently, it was necessary to perform curve-fitting for the urinary free PGME as the age-
adjusted TK model fit was not satisfactory (Figure 2). The main toxicokinetic PGME pathway 
is metabolism through the enzymes O-demethylation via microsomal enzymes 
(pentoxyresorufin O-depentylase (PROD) activity) (Miller et al., 1986) and the rate best 
described with the Michaelis-Menten model, which was governed by the parameter Vmax1 in 
our model. Vmax1 represented the maximum rate achieved by the enzyme system at maximum 
PGME concentrations. A second parameter was used to improve curve-fitting and were either 
Vmax2, describing the maximum rate of the conjugation step of PGME; Km1 the Michaels-
Menten constants for PROD activity; Km2 the Michaels-Menten constants for the conjugation 
pathway; and the parameter governing the urinary excretion rate (kur), which is known to be 
reduced in older individuals. The curve-fitting for men and women >58 years resulted in 
Vmax1=15.2 mg/h*kg0.75 and Vmax1=12.1 mg/h*kg0.75, respectively, and Vmax2=0.02 mg/h*kg0.75 
for both genders. The good fit achieved using Vmax2 as the second parameter indicated that the 
conjugation pathway was also affected. The curve-fitting achieved using Vmax1 and the 
parameter representing urinary excretion (kur) lead to equally good fit as adjusting with Vmax2. 
Adjusting the Km1 and Km2 values did not result in a better curve-fitting than Vmax1 alone (data 
not shown). Compared to the group of young volunteers (<25 years), the aging group (>58 
years) only achieved half the value for Vmax1 (Vmax1=30 mg/h*kg0.75 for young group), 
implying a slower metabolic pathway in the aging group. 
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These developed models were used to simulate occupational exposure scenarios at the current 
Swiss OEL for 8-hour/work-day and 5 days/week over four weeks. The physical workload 
was set at 50 W for 12 hours per day and at 0 W the remaining of the day. No build-up over 
the week or month was seen for the aging population (Figure 3). 
 
The urinary excretion of both free and total PGME followed an exponential decay. It is 
known that PGME follows a 0-order kinetics. We therefore calculated time-specific half-lives 
for free, conjugated, and total PGME from the fitted curves starting from when exposure 
ceased (6 hours) to the end of the urine collections (24 hours). The calculated half-lives are 
given in Table 3. 
 
To test for possible saturation, it was necessary to change the age-adjusted TK model 
(Tomicic and Droz, 2009), which had a simplified Michaels-Menten equation to incorporate 
the commonly known equation to allow for saturation in the model. Saturation of PGME 
metabolism did not occur at 50 ppm among our volunteers (i.e. linear elimination kinetics). In 
simulation runs with increasing inhalation exposures, the two models (one that allowed for 
saturation (our TK model) and one that did not (Tomicic et al., 2010)), predicted no saturation 
to occur below 100 ppm. The average total dose of PGME was calculated with PGME 
concentration (C), assumed respiratory minute volume (RMV), duration (D), and body weight 
(BW) on an “average” person, giving: 
Dose = (C (mg/l) * RMV (L/min) * D (min)) / BW = 0.188 * 15 * 360 / 70 = 14.5 mg/kg bw. 
 
Regarding the toxicological profiles in young and aging volunteers, age was found to be 
significant and accounted for about 50% of the total variance in the increasing slope of free 
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PGME (R2=0.66, p<0.0001).  No difference was detected in total PGME (as the dependent 
variable) or elimination rates. Although the kinetic curves exhibited some tendencies, the 
number of volunteers was limited and may explain the lack of significance. 
 
DISCUSSION 
In this study, we showed that PGME toxicokinetic profiles were similar among aging men 
and women (58-62 years). We also showed that the urinary PGME profiles were different for 
the group of young (20-25 years) and aging (58-62 years) volunteers exposed to PGME (50 
ppm, 6 hours), which confirms our first hypothesis. The conjugation pathway was more 
pronounced in young men, implying a slower phase II enzymatic metabolism in both young 
women without OC and aging volunteers.   
 
Conversely, the age-adjusted TK model (Tomicic and Droz, 2009) predicted well urinary total 
PGME concentrations in aging volunteers, but not urinary free PGME. These results show 
that adjusting for physiological parameters to accommodate changes in the body due to age 
was not sufficient to predict the PGME elimination in aging individuals. Adjusting the 
maximal metabolic rate (Vmax1) increased the curve-fitting for both urinary total and free 
PGME. Results from curve-fitting parameters for the conjugation pathway (Vmax2) or urinary 
excretion (kur) were equally efficient. Based on our data and model, it is difficult to choose 
which of these two parameters to use, nevertheless less conjugation was observed among the 
aging volunteers compared to the young, indicating that the conjugation pathway (Vmax2) was 
affected. 
 
Compared to the group of young men (<25 years), the aging men (>58 years) only achieved 
half the value for Vmax1 (Vmax1=30 mg/h*kg0.75 for young men), implying a slower enzymatic 
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pathway in the aging group, specially the PROD activity. PROD metabolizes the PGME α-
isomer to propylene glycol. In a recent study (Yun et al., 2010), hepatic CYP isoform levels 
were measured in aging rats, and the authors found that the expressions of CYPs were 
regulated by age in an isoform-specific manner. More specifically, the hepatic expression of 
CYP1A2, 2B1, and 2E1 decreased markedly as the rats aged. This might explain the 
difference in Vmax1 seen between young and aging men (Vmax1 aging = 12-15 mg/h*kg0.75 and 
Vmax1 young = 29 mg/h*kg0.75). Alternatively, the difference in Vmax1 between young and aging 
men could be explained by a reduced ADH and ALDH production in aging men; ADH and 
ALDH being the two enzymes which metabolizes the PGME β-isomer. On the contrary, 
women have little or no change in ADH levels as they age, and this can explain the similar 
Vmax1 value for young women not under OC treatment (Tomicic et al., 2011) and aging 
women. It remains that the ADH levels in the aging groups were similar between genders, as 
supported with our data where no gender difference in Vmax among aging individuals was 
observed (Vmax1 aging men = 15 mg/h*kg0.75 and aging women = 12 mg/h*kg0.75). However, 
since the commercial PGME product contains very small amounts of the β-isomer, the 
explanation that PROD activity diminishes with age is more plausible. 
 
In young volunteers, the men had twice the maximal metabolic rate compared to young 
women (Vmax1; young men = 30 mg/h*kg0.75 and young women = 15 mg/h*kg0.75), but similar to 
young women under hormonal treatment (OC). Hormones may change the phase I and II 
hepatic metabolizing enzymes (Kennedy, 2008), particularly when hormonal fluctuations are 
most pronounced. This might explain the differences between young women taking or not 
taking OC (Tomicic et al., 2011), and the non-differences seen between aging men and 
women where hormonal interference on biotransformation of PGME is low. Metabolizing 
enzyme expression and activity may be effected by sex steroids, and may alter the PGME 
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phase II metabolism as they are also glucuronidated. A large cross-sectional study exploring 
testosterone and estradiol levels in an aging population, showed total and free estradiol to be 
negatively associated with age in postmenopausal women (50-59 years, n=379) and positively 
associated with age in aging men (50-59 years, n=467) (Bjørnerem et al., 2004). The mean 
concentration of total estradiol in men was about twice that of postmenopausal women, and 
four times less compared to pre-menopausal women (25-39 years, n=120). There is not a clear 
cut or obvious pattern of how testosterone, estrogen and progesterone could alter PGME 
clearance. The estrogenic component of OC has shown to increase phase II drug metabolism 
via conjugation and glucuronidation (Kennedy, 2008). Estrogen levels in men increase with 
age while decrease for women, making them more similar in estrogen levels compared to 
women and men of younger ages but also prone to less glucuronidation resulting in more 
urinary excretion of free PGME. This might explain why the toxicokinetic model for the 
young only worked for the total PGME in the aging. We did not ask about the volunteers’ 
menopausal status. The activities of phase II metabolic enzymes during this hormonal status 
were therefore not assessed.  
 
The phase II metabolic enzyme pathway might not be the only explanation as physiological 
parameters in the aging body also play an important role in excretion. Reduction of the renal 
function with age affects a substance excretion rate, but also the urinary flow rate. In the 
model, the assumption was that renal functions are reduced by 30 % from young to aging 
volunteers. We found reduction in urinary flow rate from the young to the aging volunteers to 
be greater than 30% (52% in men and 41% in women) by comparing total urine volumes 
excreted after 6 hours. We obtained higher concentrations of free PGME in aging compared to 
young men, while similar values between the two groups for total PGME. The urinary 
excretion rate is not the same for free and conjugated PGME, and therefore a decrease in renal 
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function cannot explain the age difference in the ratio between free and conjugated PGME, 
but could explain the longer apparent half-life we observed (Table 3). Other physiological 
changes during aging that implicate toxicokinetics have been reviewed (Ginsberg et al 2005). 
For instance body mass indices (BMI) increase with age and result in longer half-lives by 
sequestering lipophilic substances in body fat. In our study, the volunteers BMIs were similar 
in both age groups, and are probably not a major player. Likewise, decreased plasma protein 
binding capacity can lead to increased proteinuria, which gives higher urinary concentration 
of the parent compound (Masoro and Snyder, 2001 referenced in Ginsberg et al 2005). Free 
PGME concentration was indeed higher than the conjugated PGME in aging individuals, and 
this could potentially be an alternate explanation. We did not measure protein content in the 
urine samples and cannot assess if proteinuria was common among our study participants. 
Other possible explanations are the diminished hepatic blood flow (included in the model) 
and bile flow (Zeeh and Platt 2002) seen in aging individuals. More conjugated PGME 
through bile excretion could be possible; however, since the amount excreted in urine among 
aging and young was similar (2.8 and 2.3 mg in young and aging volunteers, respectively) this 
is not very likely. The fitness of the model was enhanced by adjusting the Michaelis-Menten 
maximum rate to 1/10 of the Vmax2 for the young.  A recent review suggests that no age 
related changes in phase II metabolism occur (Mitchell et al 2011); however, this might be 
due to few studies conducted and that were performed in the 1970s. Age have also been 
demonstrated to affects elimination capabilities through glucuronidation by disturbing the 
balance between glucuronidation and deglucuronidation which vary with age, tissue, and 
substrate (Borghoff and Birnbaum 1985; Birnbaum 1991).  Furthermore, alternate 
explanations exist in that the conjugation step itself is not slower, but that the hepatic blood 
flow is less than what was assumed in the model, resulting in less PGME reaching the liver 
among aging versus young volunteers.  Another explanation is reduced glucuronide secretion 
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in the kidneys in aging individuals (Dickinson et al. 1993), which would also lead to higher 
urinary free PGME as observed in our volunteers.  These factors were not assessed in our 
study, and should be further explored in the future. As pointed out by Ginsberg and 
colleagues (2005), multiple factors may combine in aging individuals to decrease hepatic 
clearance of xenobiotics. 
The factor of saturation of the metabolic pathway was not observed among the aging 
volunteers at 50 ppm for 6 hrs at a dose of 14.5 mg/kg bw, giving 1 mg/day for a 70 kg 
person. This was in agreement with other human studies that found saturation of metabolic 
clearance to occur approximately at 7 mg/day (Speth et al., 1987). Apparent elimination half-
lives in humans have been assessed experimentally in clinical-, occupational-, and 
toxicokinetic studies. In patients, Speth et al. (1987) found a PGME half-life before saturation 
of metabolic clearance (1st order kinetics) of 2.3 hours following an intravenous (IV) 
administration. Elimination PGME half-lives were longer and followed a 0-order kinetics 
after metabolic saturation. The following apparent eliminations have been reported in the 
literature:  >3 hours when doses (IV) were above 12 g/day (Speth et al 1987); ~ 4 hours after 
repeated high doses (20.7 or 41.4 g doses given 2–3 times per day) (oral administration) (Yu 
et al., 1985); and 2.8 hours after a dose of 8.64 g (rectal administration) (n=10) (Kolloffel et 
al., 1996).  
In occupational settings, PGME apparent half-life was 1st order and estimated to 4.4 hours 
among highly exposed breakhose manufacturing workers (n=3, all men) after four days of 
PGME exposures (20 ppm) (Hubner et al 1992). The age of the workers were not reported. 
Three toxicokinetic studies exposing volunteers in an exposure chamber reported half-lives of 
<2.0 hours (n=6: two women and four men between 22-44 years, 8 hours, 100 ppm) (Jones et 
al., 1997); 1.5 hours (n=4; two women and two men between 26-45 years, 4 hours, 100 ppm); 
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and 3.5 hours (n=6; all men between 23-31 years, 6 hours, at 15, 50, and 95 ppm) 
(Devanthery et al., 2002). Only free PGME was determined in two of the toxicokinetic studies 
(Brooke et al., 1998; Jones et al., 1997), and may therefore not be directly comparable to 
Devanthery et al. (Devanthery et al., 2002) and our study. The apparent half-lives of 4.5 hours 
obtained in our study are somewhat longer than those seen for unsaturated metabolic pathway 
in patients (2.3 hours; (Speth et al., 1987)); however, they are not directly comparable as the 
administration pathways were different; inhalation (this study) and IV (Speth et al., 1987). 
The apparent PGME half-lives we found among aging volunteers were very similar to what 
has been reported previously for workers (4.4 hours; (Hubner et al., 1992)). The discordance 
between half-lives at lower concentrations (i.e. not saturated metabolic pathway) may be 
explained by the study participants’ ages; we observed a shorter PGME half-life among 
young (<25 years) volunteers with 2.2 and 3.2 hours in men and women, respectively, 
compared to the aging (>58 years) volunteers with 4.5 hours for both genders. The difference 
in apparent PGME half-life due to age could be explained by a slower metabolism in the 
aging volunteers as previously described, while the difference due to gender could be 
attributed to the competing hormonal enzymatic action. 
Half-lives may increase among individuals with impaired bladder emptying caused by 
urethral obstruction (benign prostatic hyperplasia and urethral stricture, shy bladder 
syndrome) or detrusor muscle areflexia or impared centricity (neurologic diseases damaging 
the nerves that innervate the bladder, detrusor muscle damage, anticholinergic drugs and 
reduced sensory deficit common in diabetic neuropathy patients) (Yoshimura and Chancellor, 
2004). 
Simulation of exposures to 100 ppm (occupational exposure limit for PGME in Switzerland) 
for one work-week (5 days of exposure followed by 2 days of no exposure) for one month, 
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did not show any significant build-up of PGME in the body over time (Figure 3). This is 
supported by previous published studies among breakhose manufacturing workers where no 
difference in concentrations was seen after four days of PGME exposures (Hubner et al., 
1992). However some accumulation of internal PGME dose in the body was observed using 
our model, we therefore recommend that biological monitoring is performed at the end of the 
work-week post-shift. It is also necessary to consider the half-life differences among young 
and aging workers as this will play a roll if the PGME exposures occur in the beginning of a 
work-shift or later. For example, assessing PGME exposures post-shift in men who have 
exposures (100 ppm) only early in the shift (8-9 am) will result in low exposures (12.5 ppm) 
in young men since three half-lives (T1/2=2.2 hours) will have passed, while in aging men 
exposures will be higher (15.7 ppm) because only 1.5 half-lives (T1/2=4.5 hours) will have 
occurred. The biological monitoring should be performed by determining the total (both free 
and conjugated) PGME in urine as this eliminates gender (or hormonal) and age differences.  
One limitation of our study was assumptions used in our model. We considered a PGME 
retention rate of 90% (Stott and McKenna, 1984), PGME clearance mainly through 
metabolism (90%), and the rest by renal excretion of the parent compound. Previously 
developed PBPK models for PGME, were based on rat and mouse studies, hence have slightly 
different model estimates for PGME clearance, such as 56-63% through metabolism and 11-
25% through the minor pathway, than our model (Corley et al., 1996; Corley et al., 2004; 
Kirman et al., 2005). However, human metabolic clearance of PGME has shown to be similar 
to the rabbit (Yu and Sawchuk, 1987) with 85.8-97.6% of total clearance at lower doses, and 
have been supported by another human study (Speth et al., 1987). 
 
Conclusion 
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This is the first study describing PGME inhalation toxicokinetic profiles in aging (>58 years) 
human volunteers. Results show a difference in urinary profiles according to age, where aging 
volunteers excrete higher concentration of free PGME compared to conjugated PGME than 
the young (<25 years) group in a previous study. By adjusting the maximum rates of PGME 
in the toxicokinetic model, we achieved a good fit, indicating slower phase I and II 
metabolism with age. Several age-related physiological explanations can be offered for the 
less conjugation seen among aging individuals such as changed balance between 
glucuronidation and de-glucuronidation (Borghoff and Biernbaum, 1985), decreased plasma 
protein binding capacity (Masoro and Snyder, 2001 referenced in Ginsberg et al. 2005) and 
reduced secretion of glucuronides (Dickinson et al 1994), all giving higher urinary 
concentrations of the parent compound. Another explanation is that the hepatic blood flow 
was less than assumed in the model, resulting in less PGME reaching the liver, consequently 
less conjugation among aging versus young volunteers.  Regarding the TK model, changing 
physiological parameters to reflect changes in age was not sufficient in predicting free 
PGME; however, it predicted well urinary total PGME for both young and aging individuals. 
TK models are useful, but metabolic and physiological parameters should be amended 
according to age. Gender differences in toxicokinetic profiles observed among the young 
volunteers were not observed among the aging. Consequently, for biological monitoring of 
men and women exposed to PGME, we recommend quantifying total PGME in urine. This 
would eliminate differences in conjugated and free PGME seen between young and aging, 
and genders. PGME apparent half-life in aging volunteers exposed to PGME at 50 ppm for 
six hours was 4.5 hours and followed 1st order kinetics, i.e. saturation in the PGME 
metabolism did not occur. Age is a factor that should be considered when biological limit 
values are developed because both physiological and metabolic changes due to age may play 
a significant role in type and amount of substance excreted, and its apparent half-life.  
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• PGME toxicokinetic profiles differed between age groups (>58 years vs <25 years) 
• Gender differences in PGME profiles were not observed among aging volunteers 
• For an appropriate exposure assessment, urinary total PGME should be quantified 
• Biological limit values and toxicokinetic models should include age as a factor 
Table 1 Parameters used in the initial model >58 years old 
Parameters [units] Symbol Value   Reference 
Body weight [kg] BW Men: 76.0; Women 53.7   Experimental data 
Body height  [cm] BH Men: 174; Women: 165   Experimental data 
Cardiac output [l/(h*kg
0.7
)] Qc 18.0/30.8   Thomas et al. (1996) 
Alveolar ventilation [l/(h*kg
0.7
)] Valv 18.0/2.1951*Qc   Thomas et al. (1996) 
Urinary excretion rate [ml/(h*kg
0.82
)] kur 1.294   Laparé et al. (1995) 
Molecular weight [g/mol] MW 90.12    
Threshold limit value [mg/m3] TLV 360    
Exposure concentration - modeled [mg/m3] Cexp 180    
Exposure concentration - actual [mg/m
3
] Cexp 188    
Pulmonary retention [-] Rpulm 0.9   Devanthéry (2003) 
Fraction of cardiac output in peripheral compartment [-] BF1 0.21/0.13   Thomas et al. (1996) 
Blood/air partition coefficient [-] Pblood_air 12383   Johanson et al. (1988) 
Central/air partition coefficient [-] Pc_blood 12280   Johanson et al. (1988) 
Michaelis-Menten maximum rate for metabolism [mg/(h*kg0.75]  Vmax1 27.6   Corley et al. (2005), fitted data 
Michaelis-Menten constant [mg/l] Km1 30   Corley et al. (2005), fitted data 
Michaelis-Menten maximum rate for glucoronidation [mg/(h*kg0.75] Vmax2 0.18   Corley et al. (2005), fitted data 
Michaelis-Menten constant [mg/l] Km2 95   Corley et al. (2005), fitted data 
Urinary excretion rate for conjugated PGME [h-1] kconj 0.14   Devanthéry (2003), fitted data 
      
 
 
 
Table 2 Demographics of study participants (five women and five men)  
 Age (years) 
 
 Height (m) 
 
 Weight (kg) 
 
 BMI 
 
 Women Men  Women Men  Women Men  Women Men 
Min Max 52 – 62 58 - 61  1.60 – 1.74 1.67 – 1.81  41 - 75 66 - 84  16 – 24.8 20.2 – 28.3 
            
GM (GSD) 58.5 (3.4) 59.2 (1.0)  1.65 (0.04) 1.74 (0.05)  52.9 (9.9) 75.8 (6.0)  19.5 (2.6) 24.9 (2.9) 
            
AM (SD) 58.6 (3.6) 59.2 (1.1)  1.65 (0.05) 1.74 (0.06)  53.7 (10.6) 76.0 (6.7)  19.6 (2.8) 25.1 (3.2) 
 
Table 3 Age and gender specific PGME half-lives for urinary free, conjugated, and total PGME (6-24 hours) based on modeled data 
Age Gender Hormone  
treatment 
N 
PGME half-life (hours) Ratio PGME 
  Free Conjugated
2)
 Total free/conjugated 
>58 years 
Men No 5 1.4 5.7 4.5 4.1 
Women No 5 1.2 5.5 4.5 4.6 
        
<25 years
1)
 
Men No 10 1.4 4.0 2.2 2.9 
Women with OC Yes 10 1.2 3.8 3.2 3.2 
Women without OC no 5 1.7 3.8 3.2 2.2 
        
1) Data from the study of Tomicic et al. 2011 
2) Conjugated fraction was not measured but calculated: total PGME-free PGME = Conjugated PGME 
 
 
Figure 1 Urinary total PGME concentrations (arithmetic mean and ±SD) among 
aging volunteers (>58 years, n=10) by gender (men on the left and women on 
the right) with the model developed for the young volunteers (<25 years, 
n=20)(Tomicic and Vernez, submitted 2011)(black) and the fitted model (dotted) 
Figure 2 Urinary free PGME concentrations (arithmetic mean and ±SD) among 
aging volunteers (>58 years) by gender (men on the left and women on the 
right) with the model developed for the young volunteers (<25 years, n=20) 
(Tomicic and Vernez, submitted 2011)(black) and the fitted model (dotted) 
Figure 3 Simulating PGME exposure (100 ppm) during one month of work (5 
days with and 2 days without exposure for four weeks) for aging volunteers by 
gender (men on the left and women on the right) 
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